𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

✍ Scribed by Robert G. Gish; Anna S. Lok; Ting–Tsung Chang; Robert A. de Man; Adrian Gadano; José Sollano; Kwang–Hyub Han; You–Chen Chao; Shou–Dong Lee; Melissa Harris; Joanna Yang; Richard Colonno; Helena Brett–Smith


Book ID
119760012
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
303 KB
Volume
133
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Entecavir treatment for up to 5 years in
✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB 👁 2 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E